Soltamox® (tamoxifen citrate) is the only oral liquid formulation of tamoxifen available in the US. Soltamox is indicated for adjuvant treatment of breast cancer, metastatic breast cancer, ductal carcinoma in situ and to reduce breast cancer incidence in high risk women. Soltamox is an important option for breast cancer patients who may require a liquid formulation.
In the US over 230,000 new cases of breast cancer are diagnosed each year1, and over 1.9 million prescriptions are written for tamoxifen2. Soltamox was developed to offer breast cancer patients a new option for daily tamoxifen treatment. Patients may benefit from Soltamox if they find it easier to utilize liquid medications or if they have difficulty swallowing tablets. For patients with intolerance to gluten or lactose, Soltamox is gluten and lactose free.
Soltamox is available as a sugar-free oral solution (equivalent to 10mg/5mL). Each bottle contains 150 mL.
DARA has an exclusive license to market Soltamox® in the U.S. from Rosemont Pharmaceuticals, LTD, a UK-based manufacturer and marketer of oral liquid medicines. Soltamox is patent-protected through 2018.
Tamoxifen Important Safety Information
Tamoxifen citrate is contraindicated in women who require concomitant coumadin-type anticoagulant therapy, in women with a history of deep vein thrombosis or pulmonary embolus, and in women with known hypersensitivity to the drug or any of its ingredients. Serious and life-threatening events associated with tamoxifen in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism.
The most common adverse reactions to tamoxifen treatment are (incidence > 20%) hot flashes, fluid retention, vaginal discharge, vaginal bleeding, vasodilatation, nausea, irregular menses, weight loss, and musculoskeletal events.
Tamoxifen carries the following Boxed Warning:
For a copy of the full Prescribing Information please click here.
- Cancer Facts and Figures 2014; American Cancer Society®
- Symphony Health: Total Rx data 12 months ending May, 2014